Romilkimab (SAR156597) 是一种嵌合人源化的 IG 抗体，特异性靶向 IL-4 和 IL13。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected molecular weight of Anti-IL-13 & IL-4 Reference Antibody (Romilkimab) is 197.87 kDa.

Anti-IL-13 & IL-4 Reference Antibody (romilkimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-IL-13 & IL-4 Reference Antibody (romilkimab) is 97.45%, determined by SEC-HPLC.

Romilkimab bound to IL-4 protein, and then rebounded to secondary antibodies(Anti-Human-κ+λ-HRP) , and read OD450. As shown in fig, Romilkimab bound to Human IL-4-Fc, and the EC50 was 0.040 nM.

Romilkimab bound to IL-3 protein, and then rebounded to secondary antibodies(Anti-6*his-HRP ) , and read OD450. As shown in fig, Romilkimab bound to Human IL-3-His, and the EC50 was 0.088 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.